Charles Sternberg, Associate Editor09.22.22
MiMedx Group Inc., a transformational placental biologics company, has launched Amnioeffect, a tri-layer PURION processed human tissue allograft consisting of the amnion, intermediate, and chorion membrane layers of the placenta.
Amnioeffect complements and expands the company’s Surgical Recovery product portfolio and offers superior handling characteristics and provides surgeons the capability to secure the tissue in place with sutures when needed to address a surgical wound. During the Limited Market Release (LMR) phase, Amnioeffect was used in over 50 surgical cases. Early experience has shown that the product’s handling characteristics, thickness and broad size availability are important in large debridement, limb salvage, lumbar fusion and gynecological procedures.
“The Surgical Recovery market is an engine of growth for MIMEDX,” said Rohit Kashyap, Ph.D., MIMEDX president, Wound Care & Surgical. “Our LMR experience with more than 20 surgeons confirmed that Amnioeffect services tangible unmet needs. I am encouraged by the strong level of physician interest the product has generated and confident that Amnioeffect will play a defined role in the physician tool kit. We are committed to broadening our product offering to drive deeper penetration and achieve above-market growth.”
“I am optimistic about the potential utility of Amnioeffect within an array of surgical procedures,” said Dr. Nicolas Mouawad, chief of Vascular & Endovascular Surgery, McLaren Health System – Bay Region, Bay City, Michigan and a participant in the Amnioeffect LMR. “The field of placental tissue holds tremendous promise for physicians in need of advanced treatment options for patients presenting with multiple comorbidities that can contribute to surgical complications, delayed healing, and added cost to the healthcare system. Given the product’s thicker configuration and availability in larger sizes, we will be able to treat patients needing greater coverage more effectively and efficiently in the operating room, particularly those with difficult-to-close surgical wounds.”
Amnioeffect complements and expands the company’s Surgical Recovery product portfolio and offers superior handling characteristics and provides surgeons the capability to secure the tissue in place with sutures when needed to address a surgical wound. During the Limited Market Release (LMR) phase, Amnioeffect was used in over 50 surgical cases. Early experience has shown that the product’s handling characteristics, thickness and broad size availability are important in large debridement, limb salvage, lumbar fusion and gynecological procedures.
“The Surgical Recovery market is an engine of growth for MIMEDX,” said Rohit Kashyap, Ph.D., MIMEDX president, Wound Care & Surgical. “Our LMR experience with more than 20 surgeons confirmed that Amnioeffect services tangible unmet needs. I am encouraged by the strong level of physician interest the product has generated and confident that Amnioeffect will play a defined role in the physician tool kit. We are committed to broadening our product offering to drive deeper penetration and achieve above-market growth.”
“I am optimistic about the potential utility of Amnioeffect within an array of surgical procedures,” said Dr. Nicolas Mouawad, chief of Vascular & Endovascular Surgery, McLaren Health System – Bay Region, Bay City, Michigan and a participant in the Amnioeffect LMR. “The field of placental tissue holds tremendous promise for physicians in need of advanced treatment options for patients presenting with multiple comorbidities that can contribute to surgical complications, delayed healing, and added cost to the healthcare system. Given the product’s thicker configuration and availability in larger sizes, we will be able to treat patients needing greater coverage more effectively and efficiently in the operating room, particularly those with difficult-to-close surgical wounds.”